ISMPP Highlights
The BMJ Posts ISMPP Response to First Industry Analysis of Clinical Trial Transparency Policies
The BMJ posted ISMPP’s Rapid Response on August 9, 2017, to an informative article titled, “Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study,” authored by Goldacre and colleagues, and published in The BMJ on July 26, 2017…
ISMPP Introduces New Student Membership
ISMPP has introduced a new Student Membership category, expanding its membership offerings to welcome future medical publication professionals. The Society has been exploring Student Membership for the past year, and ultimately decided to proceed with this new membership category to…
ISMPP Member Publications and Presentations
ISMPP is pleased to share these recent publications and presentations by Society members. We encourage our members to publish and present research and information related to publishing practices to advance the medical publications profession, and improve standards and best practices…
Message from Our Leadership
Robert J. Matheis
ISMPP President and CEO
News and Trends
From Reviews to In-Silico Trials: An Overview of the Publication Landscape
In the current publication landscape, medical writers and other publication professionals need to distinguish and identify the key elements that go into the various types of reviews and analyses. This article will provide an overview of review articles, meta-analyses, and computer modeling, such as in-silico trials, and how they apply to the publication landscape…
Beware the Imposter: Predatory Conferences Lure the Unsuspecting
Predatory conferences are “for-profit, low-quality academic meetings that exploit researchers’ need to share and publish their research” (1) and have been variously described as “questionable” (2), “fraudulent, bogus” (3), “fake” (4), “scam” (5), “dubious” (6), “scientifically bankrupt” (7), and “the dark side of the open access movement” (8). Predatory conferences are…
Successful Publication Steering Committees: Practice Pearls from Biopharmaceutical and Agency Perspectives
In the context of company-sponsored medical research, Good Publication Practice guidelines (GPP3) recommend the use of publication steering committees (PSCs) to “plan and oversee the development of publications and presentations from a study or group of studies.” A PSC is…
What Would You Do?
In our role as medical publication professionals, we may occasionally encounter situations in which it is not obvious how to ensure good publication practice. Have you ever wished you could consult the ISMPP membership for guidance when these situations arise? Here’s your opportunity!
What Would You Do? is a section of The MAP that presents case scenarios as an educational tool for medical publication professionals. The section provides a case scenario to ponder, and readers are invited to participate in a poll by selecting one of the listed solutions. Readers can also submit their thoughts on the scenario anonymously. The poll results, plus educational insights, are posted in a later issue for readers to digest.
POLL: Author Says “No COI” Despite Possible COI
You are a publication professional. A non-industry author states on his/her conflict of interest (COI) form that he/she has “no COI” despite your knowledge that he/she is engaged by several companies for consultancy and speaker engagements. What would you do?
ISMPP (pronounced IzMap) is the only nonprofit organization founded by medical publication professionals for medical publication professionals